Shopping Cart
- Remove All
Your shopping cart is currently empty
Cetuximab sarotalocan
😃Good
Catalog No. T9901A-037Cas No. 2166339-33-7
Alias RM-1929, Cetuximab-IRDye-700DX
Cetuximab sarotalocan (Cetuximab-IRDye-700DX) is a conjugate comprising Cetuximab, an anti-EGFR monoclonal antibody, and IRdye700DX, a near-infrared photosensitizing dye. It is utilized in the study of head and neck cancers [1] [2].
Cetuximab sarotalocan
Cetuximab sarotalocan
😃Good
Catalog No. T9901A-037Alias RM-1929, Cetuximab-IRDye-700DXCas No. 2166339-33-7
Cetuximab sarotalocan (Cetuximab-IRDye-700DX) is a conjugate comprising Cetuximab, an anti-EGFR monoclonal antibody, and IRdye700DX, a near-infrared photosensitizing dye. It is utilized in the study of head and neck cancers [1] [2].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Cetuximab sarotalocan"
Trastuzumab deruxtecan
VRN-101099, T-DXd, DS-8201a, DS 8201
T366461826843-81-5
Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.
- $728
Size
QTY
Datopotamab deruxtecan
S-1062a, DS-1062, DS1062, Dato-DXd
T397302238831-60-0
Datopotamab deruxtecan (DS-1062) is a trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) with antitumor activity. Datopotamab deruxtecan induces significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes and inhibits tumor growth in xenograft models.
- $1,060
Size
QTY
IMGC-936, IMGC936
T9901A-084
Izeltabart Tapatansine (IMGC-936) is a CHO-expressing humanized next-generation medetonin-based ADC compound targeting ADAM9-expressing tumors, and exhibits cytotoxicity against ADAM9-positive human tumor cell lines for cancer research.
- $450
Size
QTY
Disitamab vedotin
RC-48, RC48, RC 48
T395952136633-23-1
Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin showed anti-tumor and anti-proliferative activities in gastric cancer cells with different HER-2 expression levels and inhibited the expression of HER-2 protein in gastric cancer cells.
- $347
Size
QTY
Glembatumumab vedotin
CR011-vcMMAE, CR 011 ADC, CDX-011
T741781182215-65-1
Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate with potent anticancer effects, utilized in the study of triple negative breast cancer (TNBC).
- $718
Size
QTY
Sacituzumab govitecan
IMMU-132
T778241491917-83-9
Sacituzumab govitecan (IMMU-132) is a humanized ADC compound targeting Trop-2 with anticancer activity for the study of refractory, locally advanced or metastatic breast cancer and uroepithelial cancer.
- $455
Size
QTY
Brentuximab vedotin
SGN-35
T76707914088-09-8
Brentuximab vedotin (SGN-35) is a CD30-targeting antibody-active molecule conjugate (ADC) that combines a CD30 monoclonal antibody with the microtubule disrupting agent monomethylauristatin E for the study of lymphoma.
- $413
Size
QTY
Patritumab deruxtecan
U3-1287, HER3-DXd
T779102227102-46-5
Patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate (ADC), comprises a fully human anti-HER3 IgG1 monoclonal antibody, Patritumab, linked to a topoisomerase I inhibitor payload through a tetrapeptide-based cleavable linker, demonstrating anticancer activity [1].
- $797
Size
QTY
Gemtuzumab ozogamicin
T78047220578-59-6
Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a CD33-specific monoclonal antibody linked to a cytotoxic agent derived from Calicheamicin, utilized in the investigation of acute myeloid leukemia [1].
- Inquiry Price
Size
QTY
Enfortumab vedotin-ejfv
T780651346452-25-2
Enfortumab vedotin-ejfv is an antibody-drug conjugate targeting Nectin-4, employed in the treatment of urothelial carcinoma [1].
- $835
Size
QTY
Trastuzumab duocarmazine
(vic)-Trastuzumab duocarmazine
T809551642152-40-6
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is an ADC targeting HER2, cleaved by histone B within tumor cells for selective targeting, exhibiting antitumor activity and applicable in cancer research, particularly for uterine and ovarian sarcomas [1].
- Inquiry Price
Size
QTY
Sofituzumab vedotin
DMUC5754A
T811331418200-58-4
Sofituzumab vedotin (DMUC5754A) is an antibody-drug conjugate (ADC) comprising an anti-MUC16 antibody linked to monomethyl auristatin E (MMAE) via a protease-cleavable linker, utilized for cancer research [1].
- Inquiry Price
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Cetuximab sarotalocan (Cetuximab-IRDye-700DX) is a conjugate comprising Cetuximab, an anti-EGFR monoclonal antibody, and IRdye700DX, a near-infrared photosensitizing dye. It is utilized in the study of head and neck cancers [1] [2]. |
| In vitro | Cetuximab sarotalocan sodium, an antibody-photosensitive complex, combines Cetuximab, an epidermal growth factor receptor monoclonal antibody, with the dye IRdye700DX, a photosensitive substance. After administration, illumination with a red light at 690 nm [2] specifically destroys only the tumor cells. |
| Alias | RM-1929, Cetuximab-IRDye-700DX |
| Cas No. | 2166339-33-7 |
Storage & Solubility Information
| Storage | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Cetuximab sarotalocan | purchase Cetuximab sarotalocan | Cetuximab sarotalocan cost | order Cetuximab sarotalocan | Cetuximab sarotalocan in vitro
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.